Pharmaceutical market

The interactive visualisations on this page allow you to compare data across 36 OECD member countries for the following indicators of the pharmaceutical market:

  • pharmaceutical consumption
  • pharmaceutical sales
  • generic pharmaceutical market.

Key findings

In 2017 (or based on the latest year of data):  

  • total pharmaceutical sales per capita ($US purchasing power parity) were highest in Greece, at $US980. Australia’s pharmaceutical sales were equivalent to $US385 per capita
  • in Australia, the most money spent per capita, by class of pharmaceutical (other than products not elsewhere classified) was on anti-infectives for systemic use, at $US90 per capita (adjusted for purchasing power parity). This class includes pharmaceuticals such as antibiotics, vaccines, antifungals and antivirals. Australia spent the most per capita on anti-infectives for systemic use compared with 30 other OECD countries (US$90 per capita at purchasing power parity)
  • in terms of pharmaceutical consumption, in Australia the defined daily dosage per 1,000 inhabitants per day was highest for cardiovascular system pharmaceuticals (372 doses). This was also the most commonly consumed pharmaceutical on average across the OECD, though the OECD average daily dosage per 1,000 inhabitants was higher, at 444 doses
  • the proportion of the total reimbursed pharmaceutical market classed as generic pharmaceuticals in Australia was lower than the OECD average (19% compared with 24% based on value; 37% compared with 49% based on volume). Based on value, the share of generic pharmaceuticals in the reimbursed pharmaceutical market was highest in Austria (48%) and based on volume was highest in the United Kingdom (85%).